Healthcare company Baxter International (NYSE: BAX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 8% year on year to $2.97 billion. Its non-GAAP profit of $0.44 per share was 17.8% below analysts’ consensus estimates.

Is now the time to buy BAX? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Baxter’s fourth quarter results were met with a significant negative market reaction, as the company’s top-line growth did not translate into improved profitability. Management attributed the quarter’s underperformance to a mix of unfavorable product and geographic sales, nonrecurring inventory adjustments, and higher-than-expected costs, particularly in manufacturing and tariffs. CEO Andrew Hider acknowledged, “The results in the quarter are disappointing and underscore the work ahead to improve performance and execute more consistently.” The Advanced Surgery business was a bright spot, but continued operational challenges and a new baseline for IV Solutions volumes weighed on overall results.

Looking forward, Baxter’s guidance is shaped by ongoing uncertainty in its Infusion Therapies business, cost structure actions, and the rollout of new products in 2026. Management expects the first quarter to be particularly challenging, with improvements anticipated in the second half of the year as cost-saving measures and product launches gain traction. CFO Joel Grade cautioned that “organic sales growth, operating margin, and adjusted earnings per share will be back half weighted,” noting that the company’s structural changes and operational efficiency initiatives are expected to deliver gradual benefits throughout the year.

Key Insights from Management’s Remarks

Management focused on product mix headwinds, operational efficiency programs, and the impact of organizational changes as the primary factors influencing the quarter’s margin pressures and future strategic direction.

• Advanced Surgery growth: The Advanced Surgery segment delivered 11% sales growth, driven by strong demand for hemostats and sealants and broad-based commercial execution across regions. This segment was a relative bright spot in an otherwise mixed quarter.

• Infusion Therapies headwinds: The Infusion Therapies and Technologies (ITT) division faced persistent challenges, including ongoing shipment and installation holds on Novum large volume pumps and a new lower demand baseline in IV Solutions. Clinical practice changes following Hurricane Helene and evolving fluid conservation protocols continued to depress volumes.

• Margin pressure from mix and costs: Management noted that unfavorable product and geographic mix, nonrecurring inventory adjustments, and higher manufacturing and supply costs—including tariff-related expenses—were primary contributors to margin compression. Some of these pressures were partially offset by selective price increases.

• Organizational restructuring: Baxter launched a new operating model, removing a segment management layer and embedding functional roles within business units to improve accountability and accelerate decision-making. This restructuring is aimed at reducing complexity and streamlining operations but is expected to take time to fully impact results.

• Focus on operational efficiency: The company rolled out the Baxter Growth and Performance System (GPS) to drive continuous improvement, with targeted events to address inefficiencies and improve cross-business impact. Management emphasized that these efforts are ongoing and central to their turnaround strategy.

Drivers of Future Performance

Baxter’s outlook for 2026 is shaped by product pipeline launches, cost containment efforts, and lingering headwinds from mix and tariffs, with a back half-weighted recovery anticipated.

• Product launches and pipeline: Management expects new products such as the Connect 360 Monitor and Dynamo series stretcher to contribute more significantly to growth in the second half of 2026, particularly within the HealthCare Systems and Technologies segment. The continued rollout of the PureVu platform is also expected to strengthen Baxter’s pump portfolio.

• Cost structure and margin recovery: Actions to streamline operations, reduce stranded costs from the divested Kidney Care business, and align manufacturing with lower volumes are anticipated to gradually improve margins. However, higher-cost inventory rollouts and absorption headwinds will weigh on the first half.

• Tariffs and external pressures: The company forecasts $130 million to $140 million in tariff-related costs for 2026. Persistent softness in injectables and anesthesia, as well as uncertainty around Novum pump customer behavior, remain risks to both revenue and profitability.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will closely track (1) the pace and impact of new product launches such as the Connect 360 Monitor and Dynamo stretcher, (2) signs of margin stabilization as cost containment and operational efficiency initiatives take hold, and (3) updates on customer adoption and resolution timelines for the Novum pump platform. We will also monitor external cost pressures, including tariffs and evolving hospital purchasing trends, for their influence on Baxter’s execution.

Baxter currently trades at $18.91, down from $22.27 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.